Pour Demain submitted a joint contribution with 14 co-signees to the European Commission’s Call for Evidence on the EU Biotech Act, alongside colleagues from academia, industry, and civil society. Our recommendations show how embedding biosecurity into EU biotech governance can strengthen innovation, bolster strategic autonomy, and build a high-trust bioeconomy.

The following is a fictional short-story about a remote third-party general purpose AI audit, occurring within the EU in the year 2028....

Pour Demain, en collaboration avec Blueprint Biosecurity et RAND Europe, a soumis des commentaires sur deux consultations de l'UE : la...

The following is an excerpt of an op-ed published by Pour Demain in Tech Policy Press . The article provides nuance to the innovation vs...

Current geopolitical tensions and rapid technological developments have necessitated an urgent reassessment of biological risks and their...

Medical diagnostics, biomanufacturing, and many other parts of the bioeconomy rely on synthetic nucleic acids (NAs). Clinicians and...

As the European Union prepares to implement the AI Act, ensuring robust evaluation methods for General Purpose AI (GPAI) models is...

Biotech: Ensure safety to maximise progress. Safeguards needed for responsible innovation.

In an era where General Purpose AI (GPAI) models are becoming increasingly prevalent and powerful, the need for robust incident reporting...

With a return-on-investment of CHF 290 for every CHF 1 spent during an ordinary winter, savings orders of magnitudes higher during a...